Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe.

HIV Med · 2025 · PMC12400486 · PMID 40745867

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

borderline significantp = 0.059so close (0.05 < p ≤ 0.1)

Compared to 48 weeks before drug start, there was a borderline significant difference in the mean zBMI increase in the 48 weeks after drug start among those on TAF who switched from TDF ( p = 0.059); for other groups, the change in zBMI was similar before and after drug start ( p = 0.703, 0.253 and 0.971 for groups 2, 3 and 4, respectively).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.